BDI Pharma, Inc. (Formerly known as Blood Diagnostics, Inc.) Surpasses XYNTHA Distribution Projections

COLUMBIA, SC--(Marketwire - May 20, 2009) -

BDI Pharma, Inc. (BDI), the preeminent national wholesaler of specialty biopharmaceutical products, announced today that its Q1 distribution of Wyeth Pharmaceuticals’ XYNTHA Antihemophilic Factor (Recombinant) -- the manufacturer’s new Plasma-Free and Albumin-Free recombinant factor VIII product -- surpassed the company’s projected forecast for that time period. “We could not be more pleased with the market uptake and the ready acceptance of XYNTHA we have witnessed since the product’s release in the U.S.,” said William Shirey, Executive Vice President of BDI. “The antihemophilic marketplace is a highly competitive environment with a myriad of choices for the end-user. The fact that our company’s sales for XYNTHA have tracked twenty-two percent (22%) ahead of the results forecasted for the first fiscal quarter and continue to pace at an even greater rate thus far for Q2, reflects BDI’s ability to assist its trade partners with the introduction of new products, the development of brand identity and the generation of vital market share.”

XYNTHA Antihemophilic Factor (Recombinant), Plasma/Albumin-Free is approved by the U.S. Food and Drug Administration (FDA) for the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia) and for surgical prophylaxis in patients with hemophilia A. XYNTHA’s manufacturing process is albumin-free from start to finish, utilizing a unique synthetic ligand purification process totally free of animal materials and a nanofiltration step using a 35 nanometer pore-size filter. XYNTHA is Wyeth’s next generation replacement for ReFacto which exits the U.S. market on May 31, 2009.

About BDI Pharma, Inc.

Serving the healthcare community since 1995, BDI Pharma, Inc. has built an outstanding reputation as an industry source for products and service. BDI Pharma’s market focus is evident in its commitment to specialty biotherapeutics, chemotherapies, immunologics and hemostatics, including Albumin (Human) USP, intravenous immune globulin (IVIG or IGIV), coagulation factors VIII, IX, and VIIa, as well as hyper-immunes, injectables and physician specialty pharmaceuticals. As a recognized Authorized Distributor of Record for the products it supplies nationwide, BDI Pharma, Inc. services the entire country and is fully accredited and insured, fulfilling the licensing requirements in all 50 states.

In an arena where access to pertinent clinical data and updated information on market availability is paramount to patient care, BDI Pharma, Inc. defines its customer-centric approach to serving the nation’s healthcare community through innovative inventory management programs, unparalleled customer service, extensive product knowledge, unique promotional services, emergency availability and urgent need delivery. The company serves as a source for reference material and market data, offering healthcare providers the latest information on products, supply and other industry events. BDI Pharma, Inc.'s educational literature and Web site -- www.bdipharma.com -- serve as open-access resources, contributing to the promotion of the biopharmaceutical industry and the education of both the healthcare community and general populace.